Vabysmo prefilled syringe receives European approval

The European Medicines Agency approved the Vabysmo 6 mg prefilled syringe for three retinal conditions, according to a press release from Roche.

The agency approved the single-dose Vabysmo (faricimab) prefilled syringe for the treatment of wet age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion. As Healio previously reported, the prefilled syringe was approved by the FDA in July.

“Approval of the Vabysmo prefilled syringe in the EU offers a convenient way for ophthalmologists to administer this treatment for people with three of the most common causes of vision loss,” Levi Garraway, MD, PhD, Roche chief medical officer and head of global product development, said in the release. “This simplified administration may thereby help reduce the treatment burden for patients and retina specialists.”

Published by:

Read more about

This post was originally published on this site